Clinical Trial Update: A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate the safety and reactogenicity of an investigational pneumococcal vaccine in infants after a 3-dose primary series followed by a booste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Pneumonia

Drugs mentioned

• Investigational pneumococcal vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pneumonia, Bacterial | Phase 1 | Status: NOT_YET_RECRUITING